

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions of the claims presented in the application.

1-13. (Cancelled).

14. (Currently amended) A monoclonal free-end specific antibody ~~which is free-end specific for the~~ that binds specifically to a free N-terminus of an amyloid β -peptide that is soluble in cerebrospinal fluid (CSF) or to a free C-terminus of amyloid β peptide A β 1-40 that is soluble in CSF ~~, binds to said free N-terminus or said free C-terminus of soluble amyloid peptide~~ and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived.

15-22. (Cancelled)

23. (Currently amended) ~~The monoclonal~~ A single chain antibody that binds specifically to a free N-terminus of an amyloid β -peptide that is soluble in cerebrospinal fluid (CSF) or to a free C-terminus of amyloid β peptide A β 1-40 that is soluble in CSF and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived of claim 14 wherein said antibody is a single chain antibody.

24. (Previously presented) The monoclonal antibody of claim 14 wherein said antibody is free-end specific for the free N-terminus of an amyloid β -peptide.

25-32. (Cancelled)

33. (Previously presented) The monoclonal antibody of claim 14 wherein said antibody is free-end specific for the free C-terminus of the amyloid β -peptide A β 1-40.

34. (Cancelled)

35. (Currently amended) A single chain antibody in accordance with claim 23 ~~claim 24~~, which is free-end specific for the free N-terminus of amyloid β -peptide ~~A β 1-40, A β 1-42 or A β 1-43.~~

36-37. (Cancelled)

38. (New) The single chain antibody of claim 23 wherein said antibody is free-end specific for the free C-terminus of the amyloid β -peptide A β 1-40.